Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Atlantic Union Bankshares Corp

Atlantic Union Bankshares Corp reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,934 shares of the medical instruments supplier’s stock after selling 889 shares during the period. Atlantic Union Bankshares Corp’s holdings in Becton, Dickinson and Company were worth $2,789,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth about $27,000. OLD Point Trust & Financial Services N A acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. DiNuzzo Private Wealth Inc. purchased a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $30,000. Scarborough Advisors LLC acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $32,000. Finally, Rise Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $38,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BDX. Barclays lifted their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Raymond James cut their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. Finally, Citigroup decreased their price objective on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $279.50.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the transaction, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.31% of the stock is owned by insiders.

Becton, Dickinson and Company Trading Up 0.5 %

Shares of BDX stock opened at $236.38 on Friday. The company has a market capitalization of $68.32 billion, a P/E ratio of 52.07, a price-to-earnings-growth ratio of 2.06 and a beta of 0.42. The company has a current ratio of 1.85, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70. The business’s 50 day moving average is $233.26 and its two-hundred day moving average is $236.10. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $283.50.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. Becton, Dickinson and Company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the firm posted $2.96 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 13.06 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.